No­var­tis chief Vas Narasimhan wants you to know about the '25-plus’ block­busters he has in the pipeline

Vas Narasimhan has been CEO at No­var­tis for just a lit­tle more than a year since his pro­mo­tion from de­vel­op­ment chief. And in to­day’s in­vestor meet­ing, af­ter spin­ning off Al­con and putting the wheels in mo­tion to do a makeover at the suf­fer­ing gener­ics wing San­doz, the spot­light is be­ing turned straight at his prized pos­ses­sion: the pipeline.

He has a lot to boast about. But let’s start with the “25-plus” po­ten­tial block­busters in the clin­ic, along with 10-plus launch­es by 2021.

Many of these drugs are no stranger to the cen­ter ring, but there are some new ad­di­tions to the line­up.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER